Oxford BioMedica Licenses Retroviral Ex Vivo Gene Delivery Technology to MolMed SpA
The retroviral ex vivo gene delivery technology combines Oxford BioMedica's technology with some of the gene therapy technology acquired from Chiron Corporation in June this year.
Oxford BioMedica's CEO, Professor Alan Kingsman, said: "We are delighted to welcome MolMed to the list of Oxford BioMedica's technology licensees. This agreement provides further evidence of the breadth and strength of our proprietary gene delivery technology."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.